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Background: In the Netherlands about 18,000 procedures with implant removal are performed annually following
open or closed reduction and fixation of fractures, of which 30-80% concern the foot, ankle and lower leg region.
For clean surgical procedures, the rate of postoperative wound infections (POWI) should be less than ~2%. However,
rates of 10-12% following implant removal have been reported, specifically after foot, ankle and lower leg fractures.
Currently, surgeons individually decide if antibiotics prophylaxis is given, since no guideline exists. This leads to
undesirable practice variation. The aim of the study is to assess the (cost-)effectiveness of a single intravenous gift
of Cefazolin prior to implant removal following surgical fixation of foot, ankle and/or lower leg fractures.
Methods: This is a double-blind randomized controlled trial in patients scheduled for implant removal following a
foot, ankle or lower leg fracture. Primary outcome is a POWI within 30 days after implant removal. Secondary outcomes
are quality of life, functional outcome and costs at 30 days and 6 months after implant removal. With 2 x 250 patients a
decrease in POWI rate from 10% to 3.3% (expected rate in clean-contaminated elective orthopaedic trauma procedures)
can be detected (Power = 80%, 2-sided alpha = 5%, including 15% lost to follow up).
Discussion: If administration of prophylactic antibiotics prior to implant removal reduces the infectious complication
rate, this will offer a strong argument to adopt this as standard practice of care. This will consequently lead to less
physical and social disabilities and health care use. A preliminary, conservative estimation suggests yearly cost savings in
the Netherlands of € 3.5 million per year.
Trial registration: This study is registered at Clinicaltrials.gov (NCT02225821) and the Netherlands Trial Register
(NTR4393) and was granted permission by the Medical Ethical Review Committee of the Academic Medical
Centre on October 7 2014.
Keywords: Antibiotic prophylaxis, Postoperative wound infection, Implant removal, Fracture surgery,
Functional outcome* Correspondence: m.backes@amc.nl
1Trauma Unit, Department of Surgery, Academic Medical Center, University
of Amsterdam, P.O. Box 22660, 1100 DD, Amsterdam, The Netherlands
16Department of Surgery, Sint Lucas Andreas Hospital, PO Box 9243,
1006 AE, Amsterdam, The Netherlands
Full list of author information is available at the end of the article
© 2015 Backes et al.; licensee BioMed Central.
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 2 Implant removal and incidence postoperative
wound infections
Study (year) N of cases N of IR in FAL N of POWI
in FAL (%)
Raahave (1967) [4] 269 109 4 (3.7)
Richards (1992) [5] 88 25 0 (0)
Sanderson (1992) [6] 188 92 12 (13)
Minkowitz (2007) [7] 60 42 0 (0)
Schepers (2011) [9] 76 76 7 (9.2)
Backes (2013) [10] 228 69 6 (9)
Vos (2012) [2] 284 89 9 (11)
Backes (2015) [8] 512 403 49 (12.2)
N; Number, IR; implant removal NA; not available, POWI; postoperative wound
infection, FAL; foot- ankle and lower leg.
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Open or closed reduction followed by internal fixation is
a frequently performed operation for lower extremity
fractures. Indications for implant removal in adult pa-
tients include symptomatic hardware (i.e. pain, thin
overlying skin and restricted motion), implant failure
(breakage, loosening), or a persistent infectious compli-
cation of the index procedure (infection or fistula). Fol-
lowing successful surgical procedures for extremity
fractures, implant removal is not a routinely indicated
procedure. However, removal of implants causing symp-
toms can result in pain relief and a high rate of patient
satisfaction [1,2].
In the Netherlands about 18,000 implant removals are
performed annually, of which 30-80% in the foot, ankle
and lower leg region [3]. Literature on implant removal
is sparse, but studies show most of the implants re-
moved are following lower extremity injuries, especially
below the knee (Table 1).
In addition, there is only a small amount of literature
available on the risk of postoperative wound infection
(POWI) following implant removal (Table 2). For ‘clean’
procedures the rate of POWI should be less than ~2%
[11]. However, POWI rates of about 10-12%, specifically
after foot, ankle and/or lower leg fractures, have been
observed both by us and others in studies in which pa-
tients with implant removal due to an active wound in-
fection were excluded [2,8]. In syndesmotic screw
removal 9.2% of POWI were observed and in calcaneal
implant removal following fracture surgery without post-
operative complications in dislocated closed calcaneal
fractures 19% of POWI were observed [9,10]. Preopera-
tive prophylactic antibiotics might be beneficial to re-
duce the incidence of infectious complications following
implant removal.
To date, only evidence exists on the effectiveness of
prophylactic antibiotics in internal fixation with im-
plants, but not in implant removal to prevent POWI
[12]. In the Netherlands antibiotic prophylaxis is not
routinely administered prior to implant removal as it is
considered a clean procedure. Surgeons decide uponTable 1 Studies on implant removal and the portion of
implant removal from the foot-ankle and lower leg region
Study (year) N of cases N of IR FAL (%)
Raahave (1967) [4] 269 109 (41)
Richards (1992) [5] 88 25 (28)
Sanderson (1992) [6] 188 92 (49)
Minkowitz (2007) [7] 60 42 (70)
Vos (2012) [2] 284 89 (31)
Backes (2015) [8] 512 404 (79)
N; Number, IR; implant removal, FAL; foot- ankle or lower leg.themselves if antibiotics are administered prior to im-
plant removal, which is based on expert opinion as no
evidence based guideline exists. This results in a un-
desirable practice variation.
Our aim is to study the (cost-)effectiveness of a single
intravenous gift of Cefazolin prior to implant removal
following surgical fixation of foot, ankle and/or lower leg
fractures. The primary outcome is the incidence of
POWI and secondary outcomes are health-related qual-
ity of life, functional outcome, health care utilization in-
cluding transmural care, and costs from a health care
and societal perspective.
Methods
This double blind randomised controlled trial will ran-
domise between pre-operative administration of a single
gift of Cefazolin or sodium chloride 0.9% in patients
scheduled for elective implant removal below the knee.
Twenty one centers will participate, including two Level
1 trauma centers.
Participants
The eligible study population will consist of all consecu-
tive adult patients who are planned for elective implant
removal following fracture treatment of the foot, ankle
and/or lower leg.
Inclusion criteria
 Patients ≥18 years and ≤75 years of all ethnic
backgrounds
 Scheduled implant removal following foot, ankle
and/or lower leg surgery
Exclusion criteria
 Removal and adding osteosynthesis material during
the same procedure
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 Antibiotic treatment at the time of implant removal
for a concomitant disease or infection
 A medical history of an allergic reaction to a
cephalosporin, penicillin, or any other β-lactam
antibiotic
 Known kidney disease (or known eGFR <60 ml/min/
1.73 m2)
 Pregnancy and lactation
 Immunosuppressant use in organ transplantation or
rheumatoid joint disease
Interventions
After obtaining informed consent in the outpatient
clinic, patients are contacted for a pre-operative assess-






















Figure 1 Schedule of the study procedures. AB; antibiotic, POWI; postop
extremity functional Scale, iMCQ; iMTA Medical Consumption Questionnairlife by way of self-administered questionnaires before
surgery.
At the day of surgery, patients will be randomly
assigned web-based in a 1:1 allocation ratio to one of the
following study arms:
1. antibiotic prophylaxis: a single intravenous (iv) gift
of 1000 mg Cefazolin in 10 cc of NaCl 0.9%
(intervention group) or
2. no antibiotic prophylaxis: a single iv gift of 10 cc
NaCl 0.9%.
After implant removal, patients are routinely assessed
within four weeks postoperatively at the outpatient clinic
(Figure 1). They are instructed to visit the outpatient















erative wound infection, EQ-5D; EuroQuality of Life-5D, LEFS; Lower
e, iPCQ; MTA Productivity Cost Questionnaire.
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above 38.5 degrees Celsius. In case of a POWI, appropri-
ate treatment is started according to protocol. In
addition to the one time visit, the patient is asked to re-
turn a surgical wound healing post-discharge question-
naire by mail filled in at thirty days postoperatively. At
six months after implant removal, patients are contacted
by telephone or mail to fill out web-based questionnaires
to assess functional outcome, QOL measurement, pa-
tient satisfaction, health care resources utilization, costs
evaluation and questions on late infections (Figure 1).
Randomization
Randomization will be stratified per center and will be
blocked within strata. Randomization sequence is gener-
ated by a dedicated computer randomization software
program and will be performed preoperatively by a
theatre assistant and/or the anaesthesiologist using a
dedicated, password protected, SSL–encrypted website,
ensuring allocation concealment during the Time Out
Procedure. Given the randomization result, the anaes-
thesiologist will prepare either a syringe with 1000 mg
Cefazolin or with NaCl 0.9% in the operating theatre or
pre-operative holding area, which is administered thirty
minutes prior to surgery through a peripheral iv cath-
eter. The iv-catheter is used routinely for either seda-
tives, muscle relaxants and/or pain medication.
Blinding
Importantly, the anaesthesiologist prepares the study
medication in the absence of the surgeon and adminis-
ters the study medication or NaCl 0.9%. Neither the pa-
tient nor the surgeon will know if the patient receives
prophylactic antibiotics. During the visit to the out-
patient clinic the patient is seen by a physician other
than the surgeon who performed the surgery. The at-
tending physician will document signs of POWI and will
determine its presence or any special findings on phys-
ical examination. In addition, a photograph of the
wound(s) will be taken by the attending physician and
kept in the medical charts. This will enable an independ-
ent outcome assessment committee to judge the clinical
aspect of the surgical wound, blinded for the study
intervention. If the local investigator or attending phys-
ician decides unblinding is essential, (s)he will make
every effort to contact the coordinating investigator
before unblinding to discuss options. Otherwise, the
randomization code will be unblinded after analysis of
the study results.
Primary Outcome
The primary outcome variable is a POWI within 30 days
after implant removal as defined by the criteria applied
by the CDC [11].Secondary Outcomes
The study will focus on the following secondary out-
comes (Figure 1):
 Health-related quality of life as measured by the
EQ-5D questionnaire. The EQ-5D-5 L is a descriptive
system of health-related quality of life states consisting
of five dimensions (mobility, self-care, usual activities,
pain/discomfort and anxiety/depression [13].
 Functional outcome as assessed with the Lower
Extremity Functional Scale (LEFS). The LEFS is a
questionnaire containing 20 questions about a
person’s ability to perform everyday tasks and can be
used to monitor the patient over time and to evaluate
the effectiveness of an intervention [14,15].
 Patient satisfaction as measured by a ten-point
Visual Analog Scale.
 Health care resources utilization (including amongst
others, number of visits to the general practitioner
and use of home care organizations) as measured by
way of a combination of the Dutch iMTA Medical
Consumption Questionnaire (iMCQ) and iMTA
Productivity Cost Questionnaire (iPCQ).
 Costs (economic evaluation including budget impact
analysis): the economic evaluation of antibiotic
prophylaxis in patients scheduled for implant
removal following a foot, ankle or lower leg fracture
against no prophylaxis as its best alternative will be
performed as a cost-effectiveness (CEA) as well as a
cost-utility (CUA) analysis. The primary economic
outcome in the CEA will be the costs per patient
without a POWI, which closely relates to the clinical
outcome measure. The CUA outcome is the costs
per quality adjusted life year (QALY), which is a
suitable outcome measure for priority setting during
health care policy making across interventions,
patient populations, and health care settings.
Sample size
Since information from prospective studies is limited,
there is uncertainty about the POWI rate in current
medical practice. In recent Dutch prospective studies
the incidence of POWI below the knee is 11%, 12.2%,
9.2% and 19% [2,8-10]. To be on the safe side, a POWI
rate of 10% is assumed for the control group. According
to the expected rate in clean-contaminated elective
orthopedic procedures, a POWI rate of 3.3% for the
antibiotic prophylaxis group is assumed [11]. At least
216 patients per study arm are necessary to detect this
difference with a power of 80% and a two-sided alpha of
5%. An estimation of the POWI rate in the control
group is planned midway, when 216 patients have been
included and reached the primary outcome at 30 days
post-surgery. Since only an estimation of the POWI rate
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fect is tested, the overall Type I error rate is maintained.
This estimation will be performed by an independent
statistician. To allow for an anticipated drop out of 10-
15%, we will include a total of 250 patients per arm.
Based on our recent retrospective cohort studies in
both an academic and non-academic hospital an annual
number of 33–66 patients are expected to be included in
our study for implant removal following lower leg injur-
ies for each participating clinic [8]. With a number of 21
participating centers and an inclusion period of 1.5 years
the number of study participants needed, is therefore
highly feasible.
Statistical analysis
All analyses will be performed according to the intention-
to-treat principle. In addition, protocol analyses will be
done to check for robustness of results. A two-sided
P-value < 0.05 will be considered statistically signifi-
cant. In all analyses statistical uncertainties will be
quantified using corresponding 95% two-sided confidence
intervals. Descriptive analysis will be performed to com-
pare baseline characteristics between patients with and
without an infection. Univariate analysis will be performed
for primary and secondary outcomes, followed by a multi-
variate logistic regression analysis to eliminate con-
founders. All analyses will be done using the Statistical
Package for the Social Sciences (SPSS) version 19.0. (SPSS,
Chicago, Illinois, USA).
Regulation statement
The study will be conducted according to the principles
of the Declaration of Helsinki (version 10, 64th WMA
General Assembly, Forteleza, Brazil, October 2013) and
in accordance with the Medical Research Involving
Human Subjects Act (WMO) and the Good Clinical
Practice Guidelines (ICH-GCP).
Recruitment and consent
The patient will be informed about the WIFI-trial when
he or she visits the outpatient clinic and implant re-
moval is discussed. Documents are handed to the patient
and the patient is asked to read the patient information
letter. In order to be able to prepare for the elective
(day care) surgery the patient is asked to participate in
the trial during this visit to the outpatient clinic and will
be asked to sign the informed consent form. Surgeons
are asked by the coordinating investigator to check
whether patients are included in the pre-operative as-
sessment a day prior to surgery.
Benefits and risks assessment, group relatedness
Patient risks in this study are minimal and acceptable,
as Cefazolin is currently used as prophylaxis in openreduction and internal fixation of fractures. Patients in
both study groups will not be exposed to risks other
than in current practice, since there is practice variation
in the use of prophylactic antibiotics. As mentioned, cur-
rently surgeons decide upon themselves if antibiotics are
administered preoperatively. We assume that the routine
use of prophylactic antibiotics prior to implant removal
following surgical fixation of foot, ankle and/or lower leg
fractures will reduce the rate of POWI significantly (by
two-thirds, from 10% to 3.3%). If our hypothesis is sup-
ported by the results of the proposed RCT, this will offer
a strong argument to incorporate prophylactic use of a
Cefazolin as strategy of choice in (inter)national guide-
lines for implant removal following fixation of ankle,
foot and lower leg fractures. This could lead to less mor-
bidity and social adverse effects in patients like pain,
physical discomfort, multiple outpatient clinic visits/less
healthcare consumption, work absenteeism and de-
creased self-confidence.
Indemnities
The institutional review board at the AMC has waived
liability insurance, because no additional risk can be at-
tributed to participation in this study.
Publication plan
The principal investigator, the study designer and the
study coordinator will be named author. There will be a
limit of ten authors. All others will obtain group author-
ship in the study group. All authors including group
members are allowed to present the results.
Discussion
This RCT on wound infections following implant re-
moval is performed in twenty-one different hospitals by
a larger number of surgeons, which causes heterogeneity
in patients and surgeons. However, we believe this also
reflects normal practise in which antibiotic profylaxis
could be beneficial. If our assumption that prophylactic
antibiotics prior to implant removal reduces the infec-
tious complication rate is confirmed by this RCT, this
will offer a strong argument to adopt a single gift of
antibiotic prophylaxis as standard practice of care. This
will reduce the incidence of POWI and consequently will
lead to less physical and social disabilities and health care
use. In addition, it will decrease the rate of use of empiric
broad-spectrum antibiotics (and antibiotic resistance) pre-
scribed upon suspicion or diagnosis of a POWI. A prelim-
inary, conservative estimation suggests yearly cost savings
in the Netherlands of € 3.5 million per year.
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